There has been increasing interest in standardized and quantitative Epstein-Barr virus (EBV) DNA testing for the management of EBV disease. We evaluated the performance of the Real-Q EBV Quantification Kit (BioSewoom, Korea) in whole blood (WB). Nucleic acid extraction and real-time PCR were performed by using the MagNA Pure 96 (Roche Diagnostics, Germany) and 7500 Fast real-time PCR system (Applied Biosystems, USA), respectively. Assay sensitivity, linearity, and conversion factor were determined by using the World Health Organization international standard diluted in EBV-negative WB. We used 81 WB clinical specimens to compare performance of the Real-Q EBV Quantification Kit and artus EBV RG PCR Kit (Qiagen, Germany). The limit of detection (LOD) and limit of quantification (LOQ) for the Real-Q kit were 453 and 750 IU/mL, respectively. The conversion factor from EBV genomic copies to IU was 0.62. The linear range of the assay was from 750 to 10 6 IU/mL. Viral load values measured with the Real-Q assay were on average 0.54 log10 copies/mL higher than those measured with the artus assay. The Real-Q assay offered good analytical performance for EBV DNA quantification in WB.
The assessment of Epstein-Barr virus (EBV) load is important for monitoring the development of post-transplant lymphoproliferative disorder and immunosuppression in transplant patients [1] [2] [3] . Measurement of EBV DNA load has been widely implemented in clinical laboratories since the development of quantitative real-time PCR [4] . However, inter-laboratory comparisons showed significant variability in viral load results [5] . The first EBV international standard (IS) was developed and approved by WHO in 2011, which allowed for recalibration of EBV viral load assays on the basis of the standard [6] . Although the EBV IS should improve agreement between inter-laboratory test results, other factors, such as specimen type (whole blood [WB] or plasma), nucleic acid extraction method, as well as assay instruments, may affect test results [7] .
The Real-Q EBV DNA Quantification Kit (BioSewoom, Seoul, Korea) was developed for the quantification of EBV load and approved by the Korean Ministry of Food and Drug Safety [8] . It targets the EBNA1 gene and utilizes the Taqman probe-primers system. In the present study, we assessed performance of the Real-Q assay for EBV DNA quantification in WB clinical specimens using the WHO IS (code: 09/260, National Institute for Biological Standards and Control [NIBSC], Hertfordshire, UK) [6] . Nucleic acid was extracted by using the MagNA Pure 96 system (Roche Diagnostics, Mannheim, Germany), and real-time PCR was carried out by using the 7500 Fast real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). The results were compared with those obtained using the artus EBV RG PCR Kit (Qiagen, Hilden, Germany).
Briefly tuted in 1 mL of distilled water and further diluted in EBV-negative WB. The EBV-negative WB was obtained from a healthy adult and tested negative for EBV by both the artus and Real-Q assays. DNA extraction for both the artus and Real-Q assays was performed by using the MagNA Pure 96 system using the "Pathogen Universal Protocol" (elution volume of 100 μL), according to the manufacturer's instructions. For EBV DNA detection and quantification using the Real-Q assay, PCR was performed with a total volume of 25 μL (20 μL of PCR reaction mixture including probe and primer mixture and 5 μL of template DNA). Realtime PCR was carried out by using the 7500 Fast (Applied Biosystems) according to the manufacturer's instructions. Five quantitative standards (2.0, 3.0, 4.0, 5.0, and 6.0 log10 copies/μL) were included in each PCR run. The EBV DNA load was calculated from the standard curve and expressed as the number of EBV DNA copies/mL of WB. The limit of detection (LOD), the lowest concentration of viral DNA load that can be detected in 95% of replicates, was determined by using probit analysis. The limit of quantification (LOQ) was defined as the lowest level of EBV at which the total error was ≤ 1.0 log10 IU/mL [9] . Serial dilutions of the WHO IS were analyzed with eight replicates per dilution. To estimate the conversion factor, WHO IS was diluted to 5.0, 4.0, and 3.0 log10 IU/ mL in EBV-negative WB. Triplicates of the dilutions were analyzed in three consecutive days. The linearity of the real-time PCR assay was determined by analyzing a 10-fold dilution series of the WHO IS, ranging from the LOQ to 6.0 log10 IU/mL. Each dilution was tested in triplicate, and the data were subjected to a linear regression analysis. Cross-reactivity was evaluated by using nucleic acid isolated from seven viruses: cytomegalovirus, herpes simplex virus (HSV)-1, HSV-2, hepatitis B virus, BK virus, respiratory syncytial virus B, and influenza B virus. To validate the clinical performance of the Real-Q assay, 81 clinical WB specimens were used, and the results were compared with those obtained using the artus EBV RG PCR Kit (Qiagen). The characteristics of each PCR are summarized in the Supplemental Data Table 1 .
This study was conducted at a tertiary-care hospital in Seoul, Korea, and was approved by the Institutional Review Board of Samsung Medical Center. Our results showed that the LOD and LOQ of the Real-Q EBV quantification assay were 453 IU/mL and 750 IU/mL, respectively ( Table 1) . The conversion factor, calculated as the IS concentration (IU/mL) divided by the mean of 15 EBV genomic copies results (copies/mL), was 0.62. The assay was linear within the range of all samples tested (Fig. 1) A total of 81 clinical WB specimens were tested by using both the Real-Q and artus assays. Thirty-eight specimens were positive by both assays, 13 specimens were positive only by the Real-Q assay, and three specimens were positive only by the artus assay. The concordance between the two assays was 80.2% (65/81). To further compare the two assays, 38 specimens with EBV DNA load above the LOQ in both assays were analyzed by using the Bland-Altman analysis. Viral load values measured with the Real-Q assay were on average 0.54 log10 copies/mL higher than those measured with the artus assay (Fig. 2) . A Passing-Bablok regression showed a regression line of Y=1.1818 X+0.04091 (ρ=0.619, P <0.0001). The confidence interval of the slope (1.0404 to 1.5696) excluded 1, but that of the intercept (-1.7070 to 0.6152) includ ed 0, indicating a slight positive proportional bias for the Real-Q assay, but no systematic bias.
A direct comparison for EBV viral load testing can be complicated by several variables including sample type, nucleic acid extraction method, gene target, reagents used, and amplification and detection instruments [4, 10] . Semenova et al [11] demonstrated that multiple methodologies used for quantifying EBV viral load resulted in discrepancies of laboratory test results. Inter- Fig. 1 . Linearity of the Real-Q EBV Quantification Kit. laboratory variation in EBV DNA load results was reduced when WHO IS was employed to standardize the results, using the conversion factor for each test. A wide range of conversion factors, from 0.14 to 2.09, was observed in laboratories. In the present study, results obtained by using the Real-Q and artus assays show ed divergent log10 copies/mL values. However, we were unable to perform standardization of the log10 IU/mL values because conversion factor for the artus assay was not provided by the manufacturer.
Sample type is one of the most important pre-analytical variables. Various blood components such as WB, plasma or serum, peripheral blood mononuclear cells, and peripheral blood lymphocytes have been used for quantitative EBV testing [12] . Because both cell-free and intracellular viruses can be detected in WB, EBV viral load values in WB are typically higher than those in plasma [4, 12, 13] . The use of WB allows for a more convenient workflow than the use of plasma, because centrifugation is not required for the former. EBV-negative WB was used as a matrix in all performance evaluations in this study.
Nucleic acid extraction method and real-time PCR instrumentation were previously reported to affect viral load results [14] . In this study, we extracted EBV DNA by automated nucleic acid extraction using the MagNA Pure 96 system. Although we did not compare our results with those obtained using other DNA extraction methods, the Real-Q assay coupled with the MagNA Pure 96 system was a useful clinical tool for EBV quantification in WB. In conclusion, the Real-Q assay offered good analytical performance for EBV DNA quantification in WB. 
